Zealand's stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the 'weight loss Olympics'

The significant drop in Zealand's stock reflects investor sentiment that is increasingly wary of the weight-loss drug market, especially as expectations rise for more effective treatments. The CEO's remarks suggest a strategic pivot may be necessary, indicating that the company recognizes the need to redefine its approach in a saturated market. This could lead to broader implications for how companies position their weight-loss solutions moving forward.